Wall Street analysts expect Catalyst Biosciences Inc (NASDAQ:CBIO) to post earnings of ($0.59) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences reported earnings of ($2.53) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 76.7%. The firm is expected to report its next earnings results on Thursday, August 2nd.

On average, analysts expect that Catalyst Biosciences will report full year earnings of ($3.04) per share for the current financial year, with EPS estimates ranging from ($3.42) to ($2.65). For the next fiscal year, analysts forecast that the business will post earnings of ($3.92) per share, with EPS estimates ranging from ($3.96) to ($3.87). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Catalyst Biosciences.

Catalyst Biosciences (NASDAQ:CBIO) last posted its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.59. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.23 million. Catalyst Biosciences had a negative return on equity of 39.27% and a negative net margin of 2,983.40%.

A number of research firms recently weighed in on CBIO. Zacks Investment Research lowered Catalyst Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, April 26th. BidaskClub downgraded Catalyst Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, March 29th. ValuEngine upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Finally, B. Riley set a $44.00 price target on Catalyst Biosciences and gave the company a “buy” rating in a research note on Monday, May 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $49.67.

Shares of Catalyst Biosciences traded up $0.80, reaching $25.74, during trading on Monday, Marketbeat reports. 2,305 shares of the company’s stock were exchanged, compared to its average volume of 316,963. The firm has a market capitalization of $279.28 million, a PE ratio of -3.41 and a beta of 2.39. Catalyst Biosciences has a twelve month low of $3.11 and a twelve month high of $37.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CBIO. Ardsley Advisory Partners bought a new stake in Catalyst Biosciences in the 4th quarter valued at $205,000. Wells Fargo & Company MN lifted its position in shares of Catalyst Biosciences by 148.3% during the 1st quarter. Wells Fargo & Company MN now owns 8,940 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 5,340 shares during the period. Spark Investment Management LLC bought a new stake in shares of Catalyst Biosciences during the 1st quarter valued at $330,000. Geode Capital Management LLC bought a new stake in shares of Catalyst Biosciences during the 4th quarter valued at $379,000. Finally, Raymond James & Associates bought a new stake in shares of Catalyst Biosciences during the 4th quarter valued at $585,000. Institutional investors and hedge funds own 76.76% of the company’s stock.

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.